Radiopharm Theranostics Limited American Depositary Shares (RADX)

• Market cap: $37.4M
• 1 day: -3.53%
• 5 days: 2.88%
• 1 month: 0.00%
• 3 months: 18.67%
• 6 months: -2.32%
• Year to date: 0.00%
• 1 year: -73.74%
• 5 years: -73.74%
• 10 years: -73.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.01% less ownership

Funds ownership: 0.02% [Q4 2024] → 0.01% (-0.01%) [Q1 2025]

15% less capital invested

Capital invested by funds: $1.94M [Q4 2024] → $1.65M (-$290K) [Q1 2025]

25% less funds holding

Funds holding: 4 [Q4 2024] → 3 (-1) [Q1 2025]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 159% upside
• Avg. target: $15 223% upside
• High target: $18 288% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Brookline Capital Kemp Dolliver	288% upside $18	Buy Initiated	21 Jul 2025
Maxim Group Michael Okunewitch	159% upside $12	Buy Initiated	1 May 2025